🧬 This Week in Gene & Cell Therapy: Breakthrough Updates You Can’t Miss!
From groundbreaking gene therapies to major FDA updates, this week’s episode highlights the latest advances in gene and cell therapy that are reshaping medicine. Whether you’re tracking the expansion of CAR-T therapies, gene treatments for rare diseases, or breakthroughs in ALS and Rett syndrome, this episode covers it all! 🔬💡
🔍 Highlights in this episode:
⚖️ FDA investigates deaths linked to Sarepta’s Elevidys gene therapy for Duchenne muscular dystrophy
🌍 AGC Biologics expands to Asia, boosting global cell therapy manufacturing capacity
⚖️ FDA removes barriers for CAR-T access in cancer treatment, improving patient access, especially in rural areas
🧠 Neurogene’s FDA-approved trial design for Rett syndrome gene therapy NGN-401
💉 Klotho Neurosciences advances ALS gene therapy KLTO-202 into clinical trials
🧬 Biogen’s positive Phase 1 results for SMA gene therapy salanersen
🎯 A2 Biotherapeutics doses first patient in allogeneic CAR-T trial for solid tumors
💡 Qihan Biotech’s iPSC-CAR-NK cells show promise for autoimmune disease treatment
🧪 AvenCell secures $40 million grant to advance CAR-T therapy for B-cell lymphomas
🧑🔬 Abeona and Beacon collaborate to develop gene therapies for retinal diseases
🇨🇳 Carsgen’s CAR-T targeting Claudin18.2 accepted for review in China for advanced gastric cancer
❤️ Rocket Pharmaceuticals receives FDA clearance for gene therapy RP-A701 for BAG3-DCM
💡 Invetech and AiCella partner to accelerate AI-driven cell therapy manufacturing
This isn’t just a news recap—it’s your go-to pulse check on the science reshaping tomorrow’s medicine. 🎯
📢 Stay Ahead in Gene and Cell Therapy Research!
✅ Like, share, and subscribe for weekly updates on gene therapy, cell therapy, rare diseases, and biotech innovation
#GeneTherapy #CellTherapy #CAR_T #SMA #ALS #Duchenne #RettsSyndrome #BiotechNews #GeneTherapyBreakthroughs #LucidQuest #ClinicalTrials #RareDiseaseInnovation #FDAUpdates #BiotechInnovation